The global HBOT market is worth $3.98 to $7.96 billion in 2025, depending on whether you count devices only or include therapy services. It is growing at 5 to 10 percent annually. The US market alone sits at $820 million to $1.0 billion, with wound care driving 35 to 40 percent of revenue. North America holds 31 percent of global share; Asia-Pacific is growing fastest at a 6.5 percent CAGR.12
Part of the BaricBoost HBOT Data series. Cite as: “Hyperbaric Oxygen Therapy Market Size 2026: Revenue, Growth Rate & Forecast to 2032,” BaricBoost.com, 2026.
How big is the hyperbaric oxygen therapy market?
The variation between estimates comes down to scope. Devices-only estimates run $3.41 to $3.98 billion for 2025. Estimates that include therapy services (clinical treatments billed to insurance) run $4.9 to $7.96 billion.1
| Research Firm | 2025 Estimate | Forecast | CAGR | Scope |
|---|---|---|---|---|
| Fortune Business Insights | $7.96B | $14.79B (2034) | 7.13% | HBOT market (broad) |
| Research and Markets | $4.9B | $7.89B (2030) | 9.7% | Therapy market |
| Precedence Research | $3.98B | $6.71B (2034) | 5.96% | Therapy market |
| Technavio | n/a | +$177.6M growth (2030) | 6% | Therapy market |
| NovaOne Advisor | $3.41B | $5.53B (2035) | 4.95% | Devices only |
| Consensus range | $3.41B-$7.96B | $5.53B-$14.79B | ~5-7% (blended) | Devices low, broad market high |
For a single defensible figure, the therapy-market cluster centers near $4 to $5 billion in 2025 with a blended CAGR of about 5 to 7 percent. Precedence Research values the global hyperbaric oxygen therapy market at approximately $3.98 billion in 2025, projected to reach $6.71 billion by 2034 at a 5.96 percent CAGR.4
How big is the US hyperbaric oxygen therapy market?
The US HBOT market is worth roughly $0.82 to $1.0 billion in 2025 depending on scope, the largest single national market. Three research firms provide US-specific estimates:2
- Precedence Research: $1.00 billion (2025), growing to $1.72 billion by 2034 at 6.22 percent CAGR
- Nova One Advisor: $0.82 billion (2025), growing to $1.34 billion by 2035 at 5.03 percent CAGR (devices)
- Grand View Research: $0.92 billion (2024, devices), growing to $1.27 billion by 2030
North America accounts for approximately 31 percent of the global HBOT market. Registry data quantifies the Medicare side: HBOT treatments peaked at 31,389 in 2021 before falling to 25,916 in 2022, and the estimated standard-protocol cost declined to $19,488 per patient in 2022, down from $21,569 in 2013.5
How many hyperbaric chambers are there in the US?
The Undersea and Hyperbaric Medical Society (UHMS) estimates more than 1,000 hyperbaric medicine programs operate in the United States, each typically running multiple chambers.3 For a fuller breakdown, see our data hub on how many hyperbaric chambers are in the US.
For international scale, a 2020 nationwide survey found China had 1,924 institutions offering HBOT, with 2,699 chambers and 11,266 practitioners, published in Undersea and Hyperbaric Medicine.6
HBOT Capacity Snapshot
| Region | Programs / Institutions | Chambers | Source |
|---|---|---|---|
| United States (2025) | 1,000+ programs | Multiple per program | UHMS3 |
| China (2020) | 1,924 institutions | 2,699 chambers | Zhang et al., UHM 20226 |
What are the market segments?
By product type
Monoplace chambers (single-person units) dominate by revenue, at roughly 75 to 81 percent of device sales in the US, according to Grand View Research (81.02 percent, 2024).7 These are the standard in hospital wound care centers and freestanding clinics. Multiplace chambers (walk-in units serving several patients at once) are a smaller, high-value segment, with individual units costing $500,000 to over $2 million.
The portable and home chamber segment is the fastest-growing category. Consumer-grade soft chambers have brought HBOT to prices from $4,495 to $42,999, driving adoption among biohackers, athletes, and longevity users. See our sibling data hub on the home hyperbaric chamber market for segment-specific numbers.
By application
Wound care remains the largest application segment at roughly 35 to 40 percent of the market. This includes diabetic foot ulcer treatment, venous stasis ulcers, and surgical wound complications. Off-label uses for long COVID, stroke recovery, and anti-aging are growing quickly but are harder to quantify because they usually involve out-of-pocket payments.
By end user
Hospitals and wound care centers account for roughly 65 percent of the market, followed by freestanding HBOT clinics (20 to 25 percent) and home or personal use (10 to 15 percent). The home segment is growing fastest in percentage terms.
What drives hyperbaric oxygen therapy market growth?
Growth is driven by an aging population, expanding off-label evidence, falling home chamber prices, and longevity medicine. Regional dynamics vary:
- North America: about 31 percent market share, the largest installed base of chambers globally, established Medicare reimbursement for approved indications, and strong consumer wellness demand.
- Europe: roughly 25 to 30 percent. Israel punches above its weight through the Efrati and Sagol Center research program. Greater emphasis on hospital-based treatment.
- Asia-Pacific: the fastest-growing region at a 6.5 percent CAGR. China is investing heavily in facilities, and Japan has a well-established HBOT market, particularly for sports medicine.
The main demand drivers:
- Aging population: the global population aged 65 and over is projected to double by 2050, directly increasing demand for wound care and anti-aging interventions.
- Expanding off-label evidence: clinical trials for HBOT in long COVID, TBI, and stroke recovery are generating results that drive patient demand.
- Home chamber accessibility: entry-level soft chambers now start under $5,000, opening HBOT to a mass consumer market.
- Longevity medicine: HBOT has become a common protocol in the longevity movement, popularized by Bryan Johnson and linked to telomere-lengthening research.
- Sports medicine: professional teams across the NFL, NBA, Premier League, and Olympic programs use HBOT for injury recovery.
What is holding the market back?
- Insurance coverage gaps: off-label use is almost entirely out of pocket. Treatment courses cost $4,000 to $12,000 without reimbursement.
- Regulatory complexity: state-level licensing requirements vary widely across the US.
- Safety concerns: high-profile incidents like chamber fires draw disproportionate media coverage.
What is the market outlook to 2034?
The HBOT market is positioned for sustained growth from an aging population, expanding clinical evidence for off-label uses, falling home chamber prices, and rising interest in longevity and recovery. Depending on scope, the market is projected to reach $5.53 to $14.79 billion by 2034 to 2035.
The biggest upside catalyst would be FDA clearance or insurance coverage expansion for a high-demand off-label indication like long COVID or TBI. If even one major indication gained coverage, it could add billions in addressable market quickly.
Sources
- Fortune Business Insights. Hyperbaric Oxygen Therapy Market Size, 2026-2034 ($7.96B in 2025 to $14.79B by 2034, 7.13% CAGR). fortunebusinessinsights.com.
- Precedence Research. US Hyperbaric Oxygen Therapy Market ($1.00B in 2025 to $1.72B by 2034, 6.22% CAGR; North America 31% in 2024). precedenceresearch.com. 2025.
- Undersea and Hyperbaric Medical Society. Hyperbaric Facility Accreditation Program (US hyperbaric program count, estimated 1,000+). uhms.org.
- Precedence Research. Hyperbaric Oxygen Therapy Market Size 2025-2034 ($3.98B in 2025 to $6.71B by 2034, 5.96% CAGR). precedenceresearch.com. 2025.
- Fife CE, Eckert KA, et al. Trends in Medicare Costs of Hyperbaric Oxygen Therapy, 2013 through 2022. Undersea Hyperb Med. 2024;51(2). uhms.org.
- Zhang Y, Yang J, Li JS, et al. Clinical application of hyperbaric oxygen therapy in China: a 2020 baseline survey. Undersea Hyperb Med. 2022;49(2). uhms.org.
- Grand View Research. US Hyperbaric Oxygen Therapy Devices Market (monoplace 81.02% US revenue share, 2024). grandviewresearch.com.
- Nova One Advisor. Hyperbaric Oxygen Therapy Devices Market 2026-2035 (devices only, $3.41B in 2025 to $5.53B by 2035). novaoneadvisor.com.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
